Small-cell lung cancer (SCLC) is a deadly tumour accounting for approximately 15% of lung
cancers and is pathologically, molecularly, biologically and clinically very different from other …

Drug screening—ie, testing the effects of a number of drugs in multiple cell lines—is used for
drug discovery and development, and can also be performed to evaluate the heterogeneity …

Introduction The tumor microenvironment is composed of different types of stromal cells that
represent a key component of tumor progression. Cancer-associated fibroblasts (CAFs) …

Dickkopf1 (DKK1) is a secretory protein that antagonizes oncogenic Wnt signaling by
binding to the Wnt coreceptor low-density lipoprotein receptor–related protein 6 (LRP6) …

Adenocarcinoma (ADC) and squamous cell carcinoma (SqCC) are the two predominant
subtypes of non-small cell lung cancer (NSCLC) and are distinct in their histological …

Objectives Currently there are no standard biomarkers of head and neck squamous cell
carcinoma (HNSCC) response to therapy. This is, due to a lack of adequate predictive tumor …

Despite high expectations for lung tumoroids, they have not been applied in the clinic due to
the difficulty of their long-term culture. Here, however, using AO (airway organoid) media …

Patient‐derived cancer organoid culture is an important live material that reflects clinical
heterogeneity. However, the limited amount of organoids available for each case as well as …

Tumors consist of a heterogeneous mixture of functionally distinct cancer cells. These
functional differences can be caused by varying levels of receptor activity, differentiation …

Ovarian cancer (OC) is one of the leading causes of female cancer death. Recent studies
have documented its extensive variations as a disease entity, in terms of cell or tissue of …